Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet Oncology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(15)00558-6PMID 26906526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS)

  2015cited by this paper
• An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin

  2015cited by this paper
• Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved

  2015cited by this paper
• Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

  2015cited by this paper
• Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer.

  2015cited by this paper
• Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

  2014cited by this paper
• Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

  2013cited by this paper
• Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.

  2013cited by this paper
• Relationship between muscle mass and muscle strength, and the impact of comorbidities: a population-based, cross-sectional study of older adults in the United States

  2013cited by this paper
• The role of ghrelin in anorexia-cachexia syndromes.

  2013cited by this paper
• Association between body image dissatisfaction and weight loss among patients with advanced cancer and their caregivers: a preliminary report.

  2013cited by this paper
• Clinical evaluation and optimal management of cancer cachexia.

  2013cited by this paper
• Understanding the mechanisms and treatment options in cancer cachexia

  2013cited by this paper
• Megestrol acetate for treatment of anorexia-cachexia syndrome.

  2013cited by this paper
• Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

  2012cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• A phase 3 randomized, placebo‐controlled, double‐blind, clinical trial of the effect of modafinil on cancer‐related fatigue among 631 patients receiving chemotherapy

  2010cited by this paper
• Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

  2010cited by this paper
• Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment

  2009cited by this paper
• Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial.

  2007cited by this paper
• Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis.

  2006cited by this paper
• Decreased Muscle Strength and Quality in Older Adults With Type 2 Diabetes

  2006cited by this paper
• Systematic review of the treatment of cancer-associated anorexia and weight loss.

  2005cited by this paper
• Megestrol acetate for the treatment of anorexia-cachexia syndrome.

  2005cited by this paper
• Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

  2004cited by this paper
• Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.

  1997cited by this paper
• Clinical adrenal insufficiency in patients receiving megestrol therapy.

  1997cited by this paper
• Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system.

  1997cited by this paper
• Body-composition changes in patients who gain weight while receiving megestrol acetate.

  1993cited by this paper
• Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.

  1990cited by this paper
• Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

  1980cited by this paper

• The Vesicular Intersection Layer: A Framework for Cross-Kingdom Extracellular Vesicle Signaling That May Connect Gut Dysbiosis to Skeletal Muscle Wasting in Colorectal Cancer Cachexia

  2026cites this paper
• Separating food intake-dependent and -independent effects in cancer cachexia

  2026cites this paper
• Sarcopenia in Older Adults with Hematologic Malignancies: A Comprehensive Review of Epidemiology, Prognosis, and Interventions

  2026cites this paper
• Distinct Metabolomic Alterations Are Associated With Physical Function, Weight Loss, and Muscle Mass in Men With Cancer

  2026cites this paper
• The Role of New Agents and Supportive Care in a Multimodal Approach to Cancer Cachexia.

  2026cites this paper
• Prospective study of anamorelin in pancreatic cancer cachexia: Clinical and translational insights into response heterogeneity.

  2026cites this paper
• Association between dietary fiber intake and cancer cachexia: mediation by inflammatory biomarkers.

  2026cites this paper
• Methodological and reporting considerations in real-world anamarin studies of gastric cancer-related cachexia

  2026cites this paper
• A randomized controlled trial evaluating the effects of anamorelin in postoperative patients with upper gastrointestinal cancer: protocol for the CLEAR-UP study.

  2026cites this paper
• Cancer cachexia: molecular basis and therapeutic advances

  2026cites this paper
• Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)

  2026cites this paper
• High expression of the cachexia-related protein Fn14 in esophageal squamous cell carcinoma correlates with poor chemotherapy response and anti-Fn14 therapy decreases chemotherapeutic resistance

  2025cites this paper
• Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial

  2025cites this paper
• Ponsegromab: The new miracle drug for cancer cachexia

  2025cites this paper
• Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry.

  2025cites this paper
• Role of diet, physical activity and new drugs in the primary management of cancer cachexia in gastrointestinal tumors – a comprehensive review

  2025cites this paper
• Mechanisms and pharmacotherapy of cancer cachexia‐associated anorexia

  2025cites this paper
• Impact of the Timing of Initial Anamorelin Administration in Advanced Gastrointestinal Cancer With Cancer Cachexia

  2025cites this paper
• Comprehensive insights into emerging advances in the Neurobiology of anorexia

  2025cites this paper
• Novel nutrition strategies in gastric and esophageal cancer

  2025cites this paper
• Impact of Changes in Skeletal Muscle Mass Index on Prognosis During Alternating Chemoradiotherapy in Nasopharyngeal Carcinoma

  2025cites this paper
• Body composition alterations in patients with lung cancer.

  2025cites this paper
• Influence of exercise and nutrition on sarcopenia in cardiovascular disease: A Scientific Statement of the European Association of Preventive Cardiology of the ESC.

  2025cites this paper
• Cardiac Cachexia and the Associations to the Microbiome: State‐of‐the‐Science Review

  2025cites this paper
• Significant weight gain benefits of nanocrystalline megestrol acetate for patients with cancer anorexia-cachexia syndrome

  2025cites this paper
• Clinical significance of mirtazapine for anorexia in patients with non-small cell lung cancer

  2025cites this paper
• Increased protein intake in healthy males exposed to an appetite modulating, whey-derived peptide hydrolysate.

  2025cites this paper
• Effect of anamorelin on body weight in patients with gastric cancer-associated cachexia: an observational study

  2025cites this paper
• Ghrelin's role in regulating food intake among inpatients at nutritional risk: A secondary analysis of the randomized clinical trial EFFORT.

  2025cites this paper
• Bridging the tumor microenvironment: the pivotal role of cancer-associated fibroblasts in tumor cachexia development

  2025cites this paper
• Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions

  2025influential citation
• Nutritional support is beneficial in cancer patients with malnutrition and inflammation

  2025cites this paper
• Significance of Neutrophil-to-Lymphocyte Ratio in Predicting the Efficacy of Anamorelin for Cancer Cachexia

  2025cites this paper
• Concordance between EMA Good Clinical Practice inspections and medical literature concerning drugs that have not received marketing authorization in the European Union: a meta-research survey

  2025cites this paper
• Concordance between European medicine agency good clinical practice inspections and medical literature: a meta-research survey

  2025cites this paper
• Unacylated Ghrelin Counteracts Contractile and Mitochondrial Dysfunction in Cancer Cachexia

  2025cites this paper
• Revisiting Cancer Cachexia Staging: Introducing an “At Risk” Category Based on AWGC Components

  2025cites this paper
• Association between the Pretreatment Body Mass Index and Anamorelin's Efficacy in Patients with Cancer Cachexia: A Retrospective Cohort Study.

  2025cites this paper
• Impact of tumor metabolism on tumor progression and therapy Cathepsins: emerging targets in the tumor ecosystem to overcome cancers.

  2025cites this paper
• Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis

  2025cites this paper
• The Impacts of Active and Inactive Ghrelin on Cachexia and Immune Checkpoint Inhibitor Monotherapy in Patients with Non-Small Cell Lung Cancer

  2025cites this paper
• Anamorelin as a Therapeutic Option for Cancer Cachexia in Advanced Pancreatic Cancer: A Case Report Demonstrating Significant Weight Gain and Quality of Life Improvement

  2025cites this paper
• Continue to treat sarcopenia with exercise and diet while potential pharmacotherapies are under investigation

  2025influential citation
• Anamorelin Efficacy in Non–Small‐Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2

  2025cites this paper
• The Molecular Mechanisms and Treatment of Cancer-Related Cachexia.

  2025cites this paper
• Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series

  2025cites this paper
• Anamorelin in Cancer Cachexia: Gut Microbiota Effects and CONUT Score as a Predictor of Response

  2025cites this paper
• Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update

  2025cites this paper
• Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions

  2025cites this paper
• Anamorelin Induced Hyperglycemia in a Patient with Type 1 Diabetes by Stimulating Growth Hormone Secretion

  2025cites this paper
• Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non‐Small Cell Lung Cancer

  2025cites this paper
• Six‐Minute Walk Test Is Superior to Grip Strength as a Marker of Functional Recovery During Cancer Cachexia Rehabilitation

  2025cites this paper
• Ghrelin and LEAP2: Subtle Players in Cachexia, Essential for the Bigger Picture.

  2025cites this paper
• Longitudinal changes in body composition during palliative systemic chemotherapy and survival outcomes in metastatic colorectal cancer

  2025cites this paper
• Neue zielgerichtete Therapie bei der tumorassoziierten Kachexie

  2025cites this paper
• Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues

  2025influential citation
• Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor

  2025cites this paper
• Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study

  2025cites this paper
• Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial

  2025cites this paper
• Proteomic and phospho-proteomic longitudinal signatures of human skeletal muscle in lung cancer cachexia

  2025cites this paper
• Sarcopenia in Terminally Ill Patients with Cancer: Clinical Implications, Diagnostic Challenges, and Management Strategies

  2025cites this paper
• The structure and function of the ghrelin receptor coding for drug actions

  2025cites this paper
• Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.

  2025cites this paper
• A comparison of inflammatory markers’ potential to predict weight loss in advanced cancer: a prospective observational study

  2025cites this paper
• Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastaticc status.

  2025cites this paper
• Alpha‐Ketoisocaproate Attenuates Muscle Atrophy in Cancer Cachexia Models

  2025cites this paper
• Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies

  2025cites this paper
• Addressing cancer anorexia-cachexia in older patients: Potential therapeutic strategies and molecular pathways.

  2024cites this paper
• Harnessing the Systemic Biology of Functional Decline and Cachexia to Inform more Holistic Therapies for Incurable Cancers

  2024cites this paper
• Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?

  2024cites this paper
• Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.

  2024cites this paper
• Progressive, multi‐organ, and multi‐layered nature of cancer cachexia

  2024cites this paper
• Advancing cancer cachexia diagnosis with -omics technology and exercise as molecular medicine

  2024cites this paper
• Frequency of weight and body composition increases in advanced non‐small cell lung cancer patients during first line therapy

  2024cites this paper
• Ponsegromab for the Treatment of Cancer Cachexia.

  2024cites this paper
• Efficacy and safety of pharmacotherapy for cancer cachexia: A systematic review and network meta‐analysis

  2024cites this paper
• Impact of the Combination of Anamorelin and Rehabilitation on Functional and Nutritional Outcomes in Patients with Cancer Cachexia

  2024cites this paper
• Clinical Impact of Skeletal Muscle Mass and Nutritional Status in Patients with Recurrent or Advanced Gastric Cancer Treated with Nivolumab

  2024cites this paper
• The LEAP2 response to cancer-related anorexia-cachexia syndrome in male mice and patients.

  2024cites this paper
• Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case report

  2024cites this paper
• The Current Landscape of Pharmacotherapies for Sarcopenia

  2024cites this paper
• Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer

  2024cites this paper
• Central mechanisms of emesis: A role for GDF15

  2024cites this paper
• Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study

  2024cites this paper
• Long-Term Effects of Oral Nutritional Supplements After Gastrectomy for Gastric Cancer: A Survival Analysis from a Multicenter, Open-Label, Randomized Controlled Trial

  2024cites this paper
• CONUT score as a predictor for anamorelin efficacy in patients with cancer cachexia receiving chemotherapy

  2024cites this paper
• Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with a Poor Performance Status

  2024cites this paper
• In vitro pharmacological characterization of growth hormone secretagogue receptor ligands using the dynamic mass redistribution and calcium mobilization assays.

  2024cites this paper
• A Systematic Review of Cost-Effectiveness Analyses Examining Treatments for Cachexia Syndrome

  2024cites this paper
• Case report of QT interval prolongation induced by anamorelin in an obese patient with non-small cell lung cancer

  2024influential citation
• Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series

  2024cites this paper
• Understanding cachexia and its impact on lung cancer and beyond

  2024cites this paper
• Updates in Cancer Cachexia: Clinical Management and Pharmacologic Interventions

  2024cites this paper
• The efficacy and safety of anamorelin among patients with diabetes

  2024cites this paper
• Nuezhenide of the fruits of Nuzhenzi (Ligustrum lucidum Ait.) is a functional analog of ghrelin.

  2024cites this paper
• Controversies and Conundrums in Cardiac Cachexia: Key Questions About Wasting in Patients With HFrEF.

  2024cites this paper
• Cachexia Index in Patients with Gastrointestinal Cancer: A Systematic Review and Meta-Analysis

  2024cites this paper
• Mechanisms of cancer cachexia and targeted therapeutic strategies.

  2024cites this paper
• Therapeutic potential of ghrelin/GOAT/GHSR system in gastrointestinal disorders

  2024cites this paper
• Cancer cachexia: multilevel metabolic dysfunction

  2024cites this paper